BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo

Somayeh Kalanaky,1,2 Maryam Hafizi,1–3 Saideh Fakharzadeh,1 Mohammad Vasei,4 Ladan Langroudi,5 Ehsan Janzamin,6 Seyed Mahmoud Hashemi,7 Maryam Khayamzadeh,2 Masoud Soleimani,6 Mohammad Esmaeil Akbari,2 Mohammad Hassan Nazaran1 1Department of Research and Development, Sodour Ahrar Shargh Co...

Full description

Bibliographic Details
Main Authors: Kalanaky S, Hafizi M, Fakharzadeh S, Vasei M, Langroudi L, Janzamin E, Hashemi SM, Khayamzadeh M, Soleimani M, Akbari ME, Nazaran MH
Format: Article
Language:English
Published: Dove Medical Press 2015-12-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/bcc1-the-novel-antineoplastic-nanocomplex-showed-potent-anticancer-eff-peer-reviewed-article-DDDT
_version_ 1828319506268684288
author Kalanaky S
Hafizi M
Fakharzadeh S
Vasei M
Langroudi L
Janzamin E
Hashemi SM
Khayamzadeh M
Soleimani M
Akbari ME
Nazaran MH
author_facet Kalanaky S
Hafizi M
Fakharzadeh S
Vasei M
Langroudi L
Janzamin E
Hashemi SM
Khayamzadeh M
Soleimani M
Akbari ME
Nazaran MH
author_sort Kalanaky S
collection DOAJ
description Somayeh Kalanaky,1,2 Maryam Hafizi,1–3 Saideh Fakharzadeh,1 Mohammad Vasei,4 Ladan Langroudi,5 Ehsan Janzamin,6 Seyed Mahmoud Hashemi,7 Maryam Khayamzadeh,2 Masoud Soleimani,6 Mohammad Esmaeil Akbari,2 Mohammad Hassan Nazaran1 1Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 2Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Stem Cell Technology Research Center, Tehran, Iran; 4Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran; 5Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 6Department of Haematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 7Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Purpose: In spite of all the efforts and researches on anticancer therapeutics, an absolute treatment is still a myth. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In this study, for the first time, we have evaluated the anticancer effects of BCc1 nanocomplex by vitro and in vivo studies, which is designed based on the novel nanochelating technology.Methods: Human breast adenocarcinoma cell line (MCF-7) and mouse embryonic fibroblasts were used for the in vitro study. Antioxidant potential, cell toxicity, apoptosis induction, and CD44 and CD24 protein expression were evaluated after treatment of cells with different concentrations of BCc1 nanocomplex. For the in vivo study, mammary tumor-bearing female Balb/c mice were treated with different doses of BCc1 and their effects on tumor growth rate and survival were evaluated.Results: BCc1 decreased CD44 protein expression and increased CD24 protein expression. It induced MCF-7 cell apoptosis but at the same concentrations did not have negative effects on mouse embryonic fibroblasts viability and protected them against oxidative stress. Treatment with nanocomplex increased survival and reduced the tumor size growth in breast cancer-bearing balb/c mice.Conclusion: These results demonstrate that BCc1 has the capacity to be assessed as a new anticancer agent in complementary studies. Keywords: BCc1, cancer, nanotechnology, nanochelating technology, nanocomplex
first_indexed 2024-04-13T17:58:24Z
format Article
id doaj.art-e7495fdff01246fda282e9bea022d01d
institution Directory Open Access Journal
issn 1177-8881
language English
last_indexed 2024-04-13T17:58:24Z
publishDate 2015-12-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj.art-e7495fdff01246fda282e9bea022d01d2022-12-22T02:36:24ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-12-012016Issue 1597025105BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivoKalanaky SHafizi MFakharzadeh SVasei MLangroudi LJanzamin EHashemi SMKhayamzadeh MSoleimani MAkbari MENazaran MHSomayeh Kalanaky,1,2 Maryam Hafizi,1–3 Saideh Fakharzadeh,1 Mohammad Vasei,4 Ladan Langroudi,5 Ehsan Janzamin,6 Seyed Mahmoud Hashemi,7 Maryam Khayamzadeh,2 Masoud Soleimani,6 Mohammad Esmaeil Akbari,2 Mohammad Hassan Nazaran1 1Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 2Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Stem Cell Technology Research Center, Tehran, Iran; 4Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran; 5Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 6Department of Haematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 7Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Purpose: In spite of all the efforts and researches on anticancer therapeutics, an absolute treatment is still a myth. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In this study, for the first time, we have evaluated the anticancer effects of BCc1 nanocomplex by vitro and in vivo studies, which is designed based on the novel nanochelating technology.Methods: Human breast adenocarcinoma cell line (MCF-7) and mouse embryonic fibroblasts were used for the in vitro study. Antioxidant potential, cell toxicity, apoptosis induction, and CD44 and CD24 protein expression were evaluated after treatment of cells with different concentrations of BCc1 nanocomplex. For the in vivo study, mammary tumor-bearing female Balb/c mice were treated with different doses of BCc1 and their effects on tumor growth rate and survival were evaluated.Results: BCc1 decreased CD44 protein expression and increased CD24 protein expression. It induced MCF-7 cell apoptosis but at the same concentrations did not have negative effects on mouse embryonic fibroblasts viability and protected them against oxidative stress. Treatment with nanocomplex increased survival and reduced the tumor size growth in breast cancer-bearing balb/c mice.Conclusion: These results demonstrate that BCc1 has the capacity to be assessed as a new anticancer agent in complementary studies. Keywords: BCc1, cancer, nanotechnology, nanochelating technology, nanocomplexhttps://www.dovepress.com/bcc1-the-novel-antineoplastic-nanocomplex-showed-potent-anticancer-eff-peer-reviewed-article-DDDTBCc1CancerNano technologyNanochelating technologyNanocomplex
spellingShingle Kalanaky S
Hafizi M
Fakharzadeh S
Vasei M
Langroudi L
Janzamin E
Hashemi SM
Khayamzadeh M
Soleimani M
Akbari ME
Nazaran MH
BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo
Drug Design, Development and Therapy
BCc1
Cancer
Nano technology
Nanochelating technology
Nanocomplex
title BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo
title_full BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo
title_fullStr BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo
title_full_unstemmed BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo
title_short BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo
title_sort bcc1 the novel antineoplastic nanocomplex showed potent anticancer effects in vitro and in vivo
topic BCc1
Cancer
Nano technology
Nanochelating technology
Nanocomplex
url https://www.dovepress.com/bcc1-the-novel-antineoplastic-nanocomplex-showed-potent-anticancer-eff-peer-reviewed-article-DDDT
work_keys_str_mv AT kalanakys bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT hafizim bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT fakharzadehs bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT vaseim bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT langroudil bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT janzamine bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT hashemism bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT khayamzadehm bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT soleimanim bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT akbarime bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo
AT nazaranmh bcc1thenovelantineoplasticnanocomplexshowedpotentanticancereffectsinvitroandinvivo